Fax: (216) 444-9464
Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage
Version of Record online: 17 MAY 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 1, pages 136–140, 1 July 2006
How to Cite
Kalmadi, S., Tiu, R., Lowe, C., Jin, T. and Kalaycio, M. (2006), Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer, 107: 136–140. doi: 10.1002/cncr.21958
- Issue online: 16 JUN 2006
- Version of Record online: 17 MAY 2006
- Manuscript Accepted: 8 FEB 2006
- Manuscript Revised: 3 FEB 2006
- Manuscript Received: 28 DEC 2005
- thrombocytopenic hemorrhage;
- epsilon aminocaproic acid;
- adjunctive therapy;
Epsilon aminocaproic acid (EACA) is an antifibrinolytic drug that has been used to control hemorrhage by stabilizing the thrombus. It has been used in thrombocytopenic patients largely on an empiric basis.
Concerns regarding side effects have limited the use of this drug. The authors reviewed their experience with EACA at the Cleveland Clinic Foundation from 1997 to 2003.
Of 77 patients with thrombocytopenic hemorrhage, 51 (66%) patients achieved a complete response and 13 (17%) patients achieved a partial response, resulting in a decrease in platelet and red blood cell transfusions. Adverse effects were manageable in this set of patients with severe underlying disease.
Based on this experience, EACA may be a valuable adjunctive therapy in the treatment of patients with thrombocytopenic hemorrhage. Cancer 2006. © 2006 American Cancer Society.